Benzodiazepine/GABAA receptors are involved in magnesium-induced anxiolytic-like behavior in mice

Pharmacological Reports

Volumn 60, Issue 4, 2008, Pages 483-489

  Poleszak, Ewa ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Anxiety; Chlordiazepoxide; Diazepam; Elevated plus maze; Flumazenil; Magnesium; Mice

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; CHLORDIAZEPOXIDE; DIAZEPAM; FLUMAZENIL; MAGNESIUM ASPARTATE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; BEHAVIORAL RESEARCH; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ANTAGONISM; MAZE TEST; MONOTHERAPY; MOUSE; NONHUMAN; TRANQUILIZING ACTIVITY;

EID: 52049113248     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. 1A receptor agonist and NMDA receptor antagonist in the social interaction test and the elevated plus maze. Eur J Pharmacol, 1989, 169, 1-10.
2. Harvey SC: Hypnotics and sedatives In: The Pharmacological Basis of Therapeutics. Ed. Gilman AG, Goodman LS, Rall TW, Murad F, McMillan Publishing, New York, 1985, 339-371.
3. Hasey GM, D'Alessandro E, Cooke RG, Warsh JJ: The interface between thyroid activity, magnesium, and depression: a pilot study. Biol Psychiatry, 1993, 133-135.
4. Karcz-Kubicha M, Jessa M, Nazar M, Płaźnik A, Hartmann S, Parsons CG: Anxiolytic activity of glycine-B antagonists and partial agonists - no relation to intrinsic activity in the patch clamp. Neuropharmacology, 1997, 36, 1355-1367.
5. Kirov GK, Tsachev KN: Magnesium, schizophrenia and manic-depressive disease. Neuropsychobiology, 1990, 23, 79-81.
6. Kotlińska J, Liljequist S: A characterization of anxiolytic-like actions induced by the novel NMDA/glycine site antagonist, L-701,324. Psychopharmacology, 1998, 135, 175-181.
7. Lister RG: The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology, 1987, 92, 180-185.
8. MacKinnon GL, Parker WA: Benzodiazepine withdrawal syndrome: a literature review and evaluation. Am J Drug Alcohol Abuse, 1982, 9, 19-33.
9. Murck H: Magnesium and affective disorders. Nutr Neurosci, 2002, 5, 375-389.
10. Pellow S, Chopin P, File SE, Briley M: Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods, 1985, 14, 149-167.
11. Pellow S, File SE: Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav, 1986, 24, 525-529.
12. Płaźnik A, Pałejko W, Nazar M, Jessa M: Effects of antagonists at the NMDA receptor complex in two models of anxiety. Eur Neuropsychopharmacol, 1994, 4, 503-512.
13. Poleszak E, Szewczyk B, Kedzierska E, Wlaź P, Pilc A, Nowak G: Antidepressant- and anxiolytic-like activity of magnesium in mice. Pharmacol Biochem Behav, 2004, 78, 7-12.
14. Poleszak E, Wlaź P, Kedzierska E, Nieoczym D, Wyska E, Szymura-Oleksiak J, Fidecka S et al.: Immobility stress induces depression-like behavior in the forced swim test in mice: effect of magnesium and imipramine. Pharmacol Rep, 2006, 58, 746-752.
15. Poleszak E, Wlaź P, Kedzierska E, Nieoczym D, Wróbel A, Fidecka S, Pilc A, Nowak G: NMDA/glutamate mechanism of antidepressant-like action of magnesium in forced swim test in mice. Pharmacol Biochem Behav, 2007, 88, 158-164.
16. Poleszak E, Wlaź P, Wróbel A, Dybała M, Sowa M, Fidecka S, Pilc A, Nowak G: Activation of the NMDA/glutamate receptor complex antagonizes the NMDA antagonist-induced antidepressant-like effects in the forced swim test. Pharmacol Rep, 2007, 59, 595-600.
17. Przegaliński E, Tatarczyńska E, Chojnacka-Wójcik E: The influence of the benzodiazepine receptor antagonist flumazenil on the anxiolytic-like effects of CGP 37849 and ACPC in rats. Neuropsychopharmacology, 2000, 39, 1858-1864.
18. Rowley HL, Martin KF, Marsden CA: Decreased GABA release following tonic-clonic seizures is associated with an increase in extracellular glutamate in rat hippocampus in vivo. Neuroscience, 1995, 68, 415-422.
19. 2+. J Neurochem, 62, 1994, 916-922.
20. Seelig MS, Berger AR, Spielholz N: Latent tetany and anxiety, marginal magnesium deficit, and normocalcemia. Dis Nerv Syst, 1975, 36, 461-465.
21. Seelig MS: Consequences of magnesium deficiency on the enhancement of stress reactions; preventive and therapeutic implications (a review). J Am Coll Nutr, 1994, 13, 429-446.
22. Sharma AC, Kulkarni SK: Evidence for benzodiazepine receptor interaction with MK-801 in anxiety related behaviour in rats. Indian J Exp Biol, 1993, 31, 191-193.
23. Singewald N, Sinner C, Hetzenauer A, Saroti SB, Murck H: Magnesium-deficient diet alters depression- and anxiety-related behavior in mice - influence of desipramine and Hypericum perforatum extract. Neuropharmacology, 2004, 47, 1189-1197.
24. Sobolewski AI, Khodorov BI: Blocker studies of the functional architecture of the NMDA receptor channel. Neurosci Behav Physiol, 2002, 32, 157-171.
25. Stelzer A, Slater NT, Ten Bruggencate G: Activation of NMDA receptors blocks GABAergic inhibition in an in vivo model of epilepsy. Nature, 1987, 326, 698-701.
26. Steward SH, Westra HA: Benzodiazepine side-effects: from the bench to the clinic. Curr Pharm Des, 2002, 8, 1-3.
27. Thind KK, Goldsmith PC: Glutamate and GABAergic neurointeractions in the monkey hypothalamus: a quantitative immunomorphological study. Neuroendocrinology, 1995, 61, 471-485.
28. Wiley JL, Balster RL: NMDA antagonists: a novel class of anxiolytics? In: Anxiety: Neurobiology, Clinical and Therapeutic Perspectives. Ed. Hamon M, Ollat H, Thiébot MH, John Libbey Eurotext Ltd., Montrouge, France, 1993, 177-184.
29. Wiley JL, Balster RL: Preclinical evaluation of N-methyl-D-aspartate antagonists for antianxiety effects: a review. In: Multiple Sigma and PCP Receptor Ligands: Mechanisms for Neuromodulation and Neuroprotection? Ed. Kamenka JM, Domino EF, NPP Books, Ann Arbor, MI, USA, 1992, 801-815.
30. Wisden W, Stephens DN: Towards better benzodiazepines. Nature, 1999, 401, 751-752.
31. +2 block of the N-methyl-D-aspartate receptor channel. J Gen Physiol, 2001, 117, 275-286.